

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVEN	TOR	ATTORNE	EY DOCKET NO.	
09/599,213	06/22/00	WONG	E	6248	3.4	
Γ			7	EXAMINER		
1 · ·		HM12/0821		-		
JAMES J NAPOLI			JA	JARVIS,W		
MARSHALL O	TOOLE GERSTI	EIN MURRAY & BORUN	ART	UNIT F	PAPER NUMBER	
6300 SEARS	TOWER				<u> </u>	
233 SOUTH V	WACKER DRIVE		16	14	<i>(</i>)	
CHICAGO IL	60606-6402		DATE MA	AILED:	1	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

08/21/01

-	Application No.		Applicant(s)					
	09/599,213		WONG ET AL.					
Office Action Summary	Examiner		Art Unit					
	William R. Jarvis 1614							
The MAILING DATE of this communication appe Period for Reply	ars on the cover sh	eet with the co	respondence ac	ldress				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	6 (a). In no event, however within the statutory minim ill apply and will expire SIZ cause the application to b	er, may a reply be tim um of thirty (30) days K (6) MONTHS from the ecome ABANDONED	ely filed will be considered tim he mailing date of this (35 U.S.C. § 133).					
1) Responsive to communication(s) filed on	<u>.</u> .							
2a)☐ This action is FINAL . 2b)⊠ This	s action is non-fina	al.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims								
4)⊠ Claim(s) <u>1-62</u> is/are pending in the application.								
4a) Of the above claim(s) is/are withdrawn from consideration.								
5) Claim(s) is/are allowed.								
6) Claim(s) is/are rejected.								
7) Claim(s) is/are objected to.								
8) Claims 1-62 are subject to restriction and/or el	lection requiremen	t.		-				
Application Papers								
9) The specification is objected to by the Examiner.								
10) The drawing(s) filed on is/are objected to by the Examiner.								
11) The proposed drawing correction filed on is: a) approved b) disapproved.								
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. ≬ 119								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) ☐ All b) ☐ Some * c) ☐ None of:								
1. Certified copies of the priority documents	have been receive	ed.						
2. Certified copies of the priority documents have been received in Application No								
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.								
14)⊠ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).								
Attachment(s)								
15) Notice of References Cited (PTO-892) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	19) 🔲 1		(PTO-413) Paper Natent Application (F					

Application/Control Number: 09/599,213

Art Unit: 1614

Election/Restrictions

1. Claims 1-62 are generic to a plurality of disclosed patentably distinct species comprising various serotonin/norepinephrine selective compounds and conditions to be treated. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species (i.e. a particular compound and a condition to be treated), even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

2. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to William R. Jarvis whose telephone number is 703-308-4613. The examiner can normally be reached on Monday-Friday 7:30am-4:00pm.

Art Unit: 1614

Page 3

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne C. Seidel can be reached on 703-308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

William R. Jarvis (Primary Examiner Art Unit 1614

wrj August 20, 2001